Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Phil McEwan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics and Outcomes Research Ltd., Cardiff, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Sodium-Glucose Transporter 2 Inhibitors, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Recommendations on the use of newer type 2 diabetes (T2D) treatments (e.g., SGLT2 inhibitors and GLP‐1 receptor agonists [RA]) in contemporary clinical guidelines necessitate a change in how T2D models approach therapy selection and escalation. Dynamic, person‐centric clinical decision‐making considers factors beyond a patient's HbA1c and glycaemic targets, including cardiovascular (CV) risk, comorbidities and bodyweight. This study aimed to update the existing Cardiff T2D health economic model to reflect modern T2D management and to remain fit‐for‐purpose in supporting decision‐making. Materials and Methods The Cardiff T2D model's therapy selection/escalation module was updated from a conventional, glucose‐centric to a holistic approach. Risk factor progression equations were updated based on UKPDS90; the cardio‐kidney‐metabolic benefits of SGLT2i and GLP‐1 RA were captured via novel risk equations derived from relevant outcomes trial data. The significance of the updates was illustrated by comparing predicted outcomes and costs for a newly diagnosed T2D population between conventional and holistic approaches to disease management, where the latter represents recent treatment guidelines.
Results
A holistic approach to therapy selection/escalation enables early introduction of SGLT2i and GLP‐1 RA in modelled pathways in a manner aligned to guidelines and primarily due to elevated CV risk. Compared with a conventional approach, only considering HbA1c, patients experience fewer clinical events and gain additional health benefits.
Conclusions
Predictions based on a glucose‐centric approach to therapy are likely to deviate from real‐world observations. A holistic approach is more able to capture the nuances of contemporary clinical practice. T2D modelling must evolve to remain robust and relevant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Economics and Outcomes Research Ltd., Cardiff, UK.
- Diabetes Resource Centre, University Hospital Llandough, Cardiff, UK.
- UK Centre for Kidney and Bladder Health, University College London, London, UK.
- AstraZeneca R&D Pharmaceuticals, Gaithersburg, Maryland, USA.
ORCID-Profile: Phil McEwan, Geraint Roberts, Marc Evans
Förderung
- AstraZeneca
Zitieren
APA
McEwan, P., Foos, V., Roberts, G., Jenkins, R. H., Evans, M., Wheeler, D. C., & Chen, J. (2025). Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16141
Vancouver
McEwan P, Foos V, Roberts G, Jenkins RH, Evans M, Wheeler DC, et al. Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16141
BibTeX
@article{McEwan2025,
author = {McEwan, Phil and Foos, Volker and Roberts, Geraint and Jenkins, Robert H and Evans, Marc and Wheeler, David C and Chen, Jieling},
title = {Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16141}
}
EUVIMED